Inhibitory effect of Schisandrin on the pharmacokinetics of poziotinib in vivo and in vitro by UPLC‐MS / MS
Thoracic Cancer · 2023-05 · 14 (14) · 1276-1285
DOI: 10.1111/1759-7714.14870 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thoracic Cancer, online erschienen am 27.03.2023. Verfasst von Shuanghu Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: The Laboratory of Clinical Pharmacy, The Sixth Affiliated Hospital of Wenzhou Medical University, The People's Hospital of Lishui, Lishui, 323000, Ch…. Hauptthemen laut MEDLINE: Tandem Mass Spectrometry. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
As a pan‐HER tyrosine kinase inhibitor with a promising application prospect, poziotinib is likely to be coadministered with Schisandrins in clinical treatment due to its anticancer activities.
Methods
Eighteen Sprague–Dawley rats were randomly divided into three groups: Schisandrin A group and Schisandrin B group (20 mg/kg daily for 1 week), and control group (vehicle). On day 8, poziotinib (2 mg/kg) was administered by oral gavage 30 min later. An in vitro study was developed to identify the possible mechanisms of Schisandrins on poziotinib metabolism. All analytes were detected by UPLC/MS–MS, and molecular docking was performed by AutoDock Tools.
Results
When rats were preadministered with Schisandrin A, AUC (0−∞) and Cmax of poziotinib were obviously increased by 0.79‐ and 1.17‐fold, whereas the Vz/F and CLz/F values were dramatically decreased. The results in Schisandrin B group presented similarly. Both Schisandrin A and Schisandrin B were mixed inhibitors of poziotinib in RLMs, and Schisandrin B showed stronger inhibitory activity with IC 50 values of 2.55 μM for M1 and 6.97 μM for M2. Molecular docking analysis demonstrated that Schisandrin A and Schisandrin B exhibited a strong binding ability towards CYP2D6 as compared to CYP3A4.
Conclusion
All results provided the direct evidence of the pharmacokinetic drug–drug interactions (DDIs) between Schisandrin and poziotinib. Thus, particular attention should be paid when poziotinib is taken together with Schisandrins in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Laboratory of Clinical Pharmacy, The Sixth Affiliated Hospital of Wenzhou Medical University, The People's Hospital of Lishui, Lishui, 323000, China.
- Department of Pharmacy, Ningbo Medical Center Lihuili Hospital, Ningbo, 315100, China.
- The Key Laboratory of Geriatrics, Beijing Institute of Geriatrics, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Hospital/National Center of Gerontology of National Health Commission, Bei…
- Department of Thoracic Surgery, Beijing Hospital, National Center of Gerontology, Beijing, China.
ORCID-Profile: Shuanghu Wang, Dapeng Dai, Qingjun Wu
Zitieren
APA
Wang, S., Xia, M., Wang, Y., Lu, Z., Geng, P., Dai, D., Zhou, Y., & Wu, Q. (2023). Inhibitory effect of Schisandrin on the pharmacokinetics of poziotinib in vivo and in vitro by UPLC‐MS / MS. Thoracic Cancer, 14(14), 1276-1285. https://doi.org/10.1111/1759-7714.14870
Vancouver
Wang S, Xia M, Wang Y, Lu Z, Geng P, Dai D, et al. Inhibitory effect of Schisandrin on the pharmacokinetics of poziotinib in vivo and in vitro by UPLC‐MS / MS. Thoracic Cancer. 2023;14(14):1276-1285. doi:10.1111/1759-7714.14870
BibTeX
@article{Wang2023,
author = {Wang, Shuanghu and Xia, Mengming and Wang, Yu and Lu, Zebei and Geng, Peiwu and Dai, Dapeng and Zhou, Yunfang and Wu, Qingjun},
title = {Inhibitory effect of Schisandrin on the pharmacokinetics of poziotinib in vivo and in vitro by UPLC‐MS / MS},
journal = {Thoracic Cancer},
year = {2023},
volume = {14},
number = {14},
pages = {1276--1285},
doi = {10.1111/1759-7714.14870}
}
EUVIMED